Contineum Therapeutics (CTNM) Profit After Tax (2023 - 2026)

Contineum Therapeutics' Profit After Tax history runs 4 years deep, the most recent figure standing at -$14.5 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 9.32% year-over-year to -$14.5 million in Q1 2026; TTM through Mar 2026 was -$58.5 million, a 17.33% decrease from a year earlier, with the FY2025 full-year figure at -$60.0 million, down 41.86% from the prior year.
• Profit After Tax improved to -$14.5 million in Q1 2026 per CTNM's latest filing, from -$15.2 million in the prior quarter.
• Across five years, Profit After Tax topped out at $41.6 million in Q2 2023 and bottomed at -$16.0 million in Q2 2025.
• The 4-year median for Profit After Tax is -$10.3 million (2024), against an average of -$7.2 million.
• Across the five-year window, Profit After Tax plunged 121.68% in 2024 and grew 9.32% in 2026, its largest moves.
• Year by year, Profit After Tax stood at -$7.6 million in 2023, then slumped by 92.84% to -$14.6 million in 2024, then retreated by 3.94% to -$15.2 million in 2025, then advanced by 4.47% to -$14.5 million in 2026.
• Per Business Quant, the three latest CTNM Profit After Tax figures stand at -$14.5 million (Q1 2026), -$15.2 million (Q4 2025), and -$12.8 million (Q3 2025).